Microfluidic-Based Technologies for CTC Isolation: A Review of 10 Years of Intense Efforts towards Liquid Biopsy - Archive ouverte HAL Access content directly
Journal Articles International Journal of Molecular Sciences Year : 2022

Microfluidic-Based Technologies for CTC Isolation: A Review of 10 Years of Intense Efforts towards Liquid Biopsy

Abstract

The selection of circulating tumor cells (CTCs) directly from blood as a real-time liquid biopsy has received increasing attention over the past ten years, and further analysis of these cells may greatly aid in both research and clinical applications. CTC analysis could advance understandings of metastatic cascade, tumor evolution, and patient heterogeneity, as well as drug resistance. Until now, the rarity and heterogeneity of CTCs have been technical challenges to their wider use in clinical studies, but microfluidic-based isolation technologies have emerged as promising tools to address these limitations. This review provides a detailed overview of latest and leading microfluidic devices implemented for CTC isolation. In particular, this study details must-have device performances and highlights the tradeoff between recovery and purity. Finally, the review gives a report of CTC potential clinical applications that can be conducted after CTC isolation. Widespread microfluidic devices, which aim to support liquid-biopsy-based applications, will represent a paradigm shift for cancer clinical care in the near future.
Fichier principal
Vignette du fichier
ijms-23-01981-v2.pdf (6.89 Mo) Télécharger le fichier
Origin Publisher files allowed on an open archive
Licence

Dates and versions

hal-03599242 , version 1 (07-03-2022)

Licence

Identifiers

Cite

Lucie Descamps, Damien Le Roy, A.-L. Deman. Microfluidic-Based Technologies for CTC Isolation: A Review of 10 Years of Intense Efforts towards Liquid Biopsy. International Journal of Molecular Sciences, 2022, 23 (4), pp.1981. ⟨10.3390/ijms23041981⟩. ⟨hal-03599242⟩
40 View
85 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More